Generate Biomedicines, Inc. (GENB) Generate Biomedicines, Inc. is a U.S.-based company pioneering generative biology, leveraging machine learning for the discovery and advancement of novel protein therapeutics. Their core approach involves developing drugs using protein-based modalities. The company's pipeline includes several key candidates: GB-0895, an investigational long-acting anti-TSLP monoclonal antibody designed for bi-annual dosing in severe asthma; GB-4362, an MMAE payload neutralizer monoclonal antibody; and GB-5267, a MUC16 CAR-T cell therapy. Integral to their work is the Generate Platform, a sophisticated system engineered to be versatile across diverse therapeutic areas and protein modalities. This platform combines computational innovation with scalable biohardware, allowing them to tackle therapeutic hurdles beyond the capabilities of traditional technologies. Established in 2018, the company was initially known as Generate Biologics, Inc. before rebranding to Generate Biomedicines, Inc. in February 2020. Its headquarters are located in Somerville, Massachusetts.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Generate Biomedicines, Inc. NASDAQ:GENB Financial Services · Asset Management
Mkt Cap $1.86B
Vol 0
$ Vol 0
RVOL 0
Earnings 0
Press Release
Generate Biomedicines to Participate in November Investor Conferences
Generate Biomedicines announced management presentations at two November investor conferences: the Guggenheim 3rd Annual Healthcare Innovation Conference in Boston on Nov. 9 and the Jefferies Global Healthcare Conference in London on Nov. 16.
Live webcasts will be available on the company's investor relations website, with replays posted for 90 days following each event.
This is a routine scheduling notice with no financial results, guidance, or pipeline data included.
• 10d ago AI analysis › Press Release ⚠ 1
Generate Biomedicines and Zealand Pharma Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases
Generate Biomedicines entered a multi-target collaboration and license agreement with Zealand Pharma to design multispecific protein therapeutics for obesity and metabolic diseases using Generate's generative AI platform.
Generate will receive $30M upfront plus up to $35M in early preclinical milestones, and is eligible for up to nearly $1.2B in total milestones plus tiered royalties on worldwide net sales for two initial programs, with an option to add a third.
Generate leads research through lead-candidate selection; Zealand assumes clinical development, regulatory submissions, and worldwide commercialization — validating Generate's AI platform and extending it beyond peptides into obesity.
• 19d ago AI analysis › Press Release ● Major
Zealand Pharma and Generate Biomedicines Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases
Generate Biomedicines signed a multi-target collaboration and license agreement with Zealand Pharma to design multispecific protein therapeutics for obesity and other metabolic diseases using generative AI.
Generate will receive $30 million upfront, up to $35 million in early preclinical milestones, and total milestones of nearly $1.2 billion plus tiered royalties for two initial programs, with an option to add a third.
Generate leads research through lead-candidate selection using The Generate Platform; Zealand assumes clinical development, regulatory submissions, and worldwide commercialization.
• 19d ago AI analysis › Press Release ⚠ 2
Roswell Park, Generate Biomedicines Launch Exclusive Clinical Trial of ‘Armored’ CAR T Therapy for Ovarian Cancer
Generate Biomedicines and Roswell Park dosed the first patient in a first-in-human Phase 1 trial (NCT07489287) of GB-5267, an IL-18-armored autologous CAR T-cell therapy for platinum-resistant ovarian cancer.
GB-5267 targets MUC16, over-expressed in more than 80% of ovarian tumors, and was designed with AI to optimize potency, proliferation, and persistence in solid tumor microenvironments.
Unlike many CAR T approaches, the trial requires no lymphodepletion chemotherapy, and dosing includes both intravenous and intraperitoneal delivery.
• 1mo ago AI analysis › Press Release
Generate Biomedicines Inc. to Participate in September Investor Conferences
Generate Biomedicines announced that members of its management team will present at five investor conferences in September, beginning with the Cantor Global Healthcare Conference on Sept. 9 at 3:55 p.m. ET.
The remaining appearances are the Morgan Stanley Global Healthcare Conference (Sept. 14), Goldman Sachs Life Sciences Symposium (Sept. 15), H.C. Wainwright Global Investment Conference (Sept. 16), and Bernstein Insights Healthcare Leaders and Disruptors (Sept. 23), all in New York.
Live webcasts will be available on the company's investor website, with replays archived for 90 days.
This is a routine IR scheduling notice containing no new clinical, financial, or guidance data for the clinical-stage generative biology company.
• 1mo ago AI analysis › Press Release ⚠ 2
Generate Biomedicines Inc. Reports Second Quarter 2026 Financial Results and Provides Business Update
Generate Biomedicines reported Q2 2026 revenue of $6.3 million, down from $10.1 million in the prior year, with a net loss of $67.3 million driven by increased R&D investment.
The company maintained a strong balance sheet with $457.4 million in cash and marketable securities, which it expects will fund operations into the first half of 2028.
Pipeline milestones include the ongoing global recruitment for the Phase 3 SOLAIRIA studies of GB-0895 in severe asthma and the dosing of the first cohort in the Phase 1 study of GB-4362.
• 2mo ago AI analysis › Press Release
AdvanCell Signs 128,000 Square Foot, Full Building Lease at IQHQ's Innovation Park in Andover, Massachusetts
IQHQ announced that AdvanCell signed a 128,000 square foot lease at Innovation Park in Andover, Massachusetts, bringing the newly constructed Phase 2 to 100% leased.
The release notes that Generate Biomedicines (GENB) is an existing tenant on campus and references its approximately $400 million IPO in February 2026.
No material business updates or operational changes were disclosed regarding Generate Biomedicines.
• 4mo ago AI analysis › Press Release
Generate Biomedicines Inc. to Participate in Goldman Sachs 47th Annual Global Healthcare Conference
Generate Biomedicines announced it will participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 8, 2026.
A live webcast and archived replay of the presentation are expected to be available on the company's investor website.
The release contains no new operational, clinical, or financial disclosures beyond the conference attendance.
• 5mo ago AI analysis › Press Release ● Major
Generate Biomedicines, Inc. Reports First Quarter 2026 Financial Results and Provides Business Update
Generate Biomedicines reported Q1 revenue of $7.2 million and ended the quarter with $516.6 million in cash, providing a runway into the first half of 2028.
Clinical pipeline progress included continued Phase 3 advancement for GB-0895, FDA Fast Track designation for GB-4362, and expected first patient dosing for GB-5267 in H2 2026.
R&D expenses increased to $57.8 million, driven by the GB-0895 Phase 3 program, while net loss widened to $61.7 million year-over-year.
• 5mo ago AI analysis › Press Release ● Critical
Generate Biomedicines, Inc. Announces Pricing of Initial Public Offering
prnewswire.com • 8mo ago 
